DermAvance Pharmaceuticals Announce the publication of a study demonstrating efficacy of Hyalogy-nano-hyaluronic acid in humans

Malvern, Pa. March 2014-DermAvance Pharmaceuticals a privately held pharmaceutical company specializing in advanced technology for aging skin, today announce the publication of a clinical study in humans demonstrating the efficacy of a new topical nano-hyaluronic acid product line called Hyalogy. The study was the lead article published in The Journal of Clinical Aesthetic Dermatology March 2014 Volume 7, Number 3, and demonstrated Hyalogy Skin Care proved the following results;

• Skin Hydration measured with corneometer after 57 days increased skin moisture up to 96%
• Wrinkles roughness was assessed by capturing 3D structure and the depth of wrinkles was reduced up to 40%
• Skin Firmness or elasticity measured by Cutometer after 57 days showed up to 55% enhancement
• Redness or erythema measured with a Chromameter after 57 days showed up to a 35% decrease

“We are very pleased with this controlled data in humans being published, and it demonstrates the true advantage of Hyalogy^®(nano-hyaluronic acid)  skin care patented manufacturing process of ultra low molecular hyaluronic acid to penetrate the skin barrier and rejuvenate the skin” says Keith Greathouse, DermAvance President and CEO.